A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Public ClinicalTrials.gov record NCT03445533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
Study identification
- NCT ID
- NCT03445533
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 481 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2018
- Primary completion
- May 31, 2021
- Completion
- May 31, 2021
- Last update posted
- Nov 7, 2022
2018 – 2021
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) | Birmingham | Alabama | 35294 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Cancer Treatment Centers of America (CTCA) - Western Regional Medical Center | Scottsdale | Arizona | 85338 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Sutter Health Sacramento | Sacramento | California | 95816 | — |
| University of California, San Diego (UCSD) - Moores Cancer Center | San Diego | California | 92093 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Mount Sinai Medical Center of Florida, Inc. | Miami Beach | Florida | 33140 | — |
| University of Florida Health Cancer Center - Orlando Health | Orlando | Florida | 32806 | — |
| The Valley Hospital | Ridgewood | New Jersey | 07450 | — |
| University of Cincinnati Health | Cincinnati | Ohio | 45219 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James) | Columbus | Ohio | 43221 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Inova Health Care Services | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03445533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2022 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03445533 live on ClinicalTrials.gov.